Last reviewed · How we verify
intravenous iron
At a glance
| Generic name | intravenous iron |
|---|---|
| Also known as | i.v. iron, Venofer, Encifer, erythropoietin, Venofer, ferinject |
| Sponsor | Federal Teaching Hospital Abakaliki |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Bevacizumab In Hereditary Hemorrhagic Telangiectasia (PHASE2)
- Iron and Immune Response to Vaccine (IRONMUM) (NA)
- Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome (PHASE4)
- Oral Versus Intravenous Iron for Anemia Diagnosed After 34 Weeks of Gestation (NA)
- Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study (PHASE3)
- Patient Blood Management in Cardiac Surgery (NA)
- A Phase 1 Study of PVT401 in Healthy Subjects (PHASE1)
- Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intravenous iron CI brief — competitive landscape report
- intravenous iron updates RSS · CI watch RSS
- Federal Teaching Hospital Abakaliki portfolio CI